Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation.

Anette Lodvir Hemsing, Bjørn Tore Gjertsen, Signe Spetalen, Lars Helgeland, Håkon Reikvam

Open access · goldAbstract readCase Reports

In one paragraph

Article in SAGE open medical case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 99% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Anette Lodvir HemsingSection of Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway.ORCID https://orcid.org/0000-0002-1567-1099

Bjørn Tore GjertsenSection of Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway.

Signe SpetalenDepartment of Pathology, Oslo University Hospital, Oslo, Norway.

Lars HelgelandDepartment of Pathology, Haukeland University Hospital, Bergen, Norway.

Håkon ReikvamSection of Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway.ORCID https://orcid.org/0000-0001-5439-8411

Haukeland University Hospital · NOOslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The entity myelodysplastic syndrome/myeloproliferative neoplasm overlap syndrome is characterized by the coexistence of both myeloproliferative and myelodysplastic features in the bone marrow. Risk assessment and treatment recommendations have not been standardized, and clinicians rely on updated patient studies and reviews to make decisions for treatment approaches. Histopathological features have traditionally been important, although in the last decade, several studies have reported mutational profiles of this rare disease. Here, we present a case, wherein the patient presented with leukocytosis and the diagnostic work-up revealed features of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndrome. Mutational profiling revealed mutations in four genes associated with myeloid malignancies, namely,

Indexed as

allogeneic hematopoietic stem cell transplantationapproachesMutational profilemyelodysplasticmyeloproliferativeoverlap syndrome

Identifiers

PMID33628448

DOI10.1177/2050313X20988413

PMCPMC7841861

OpenAlexW3123958779

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.